Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial.
Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, De Boer H, Smeenk RJ, Kunze-Busch M, Monninkhof EM, De Roover R, Isebaert S, Kerkmeijer LGW. Draulans C, et al. Among authors: smeenk rj. Radiother Oncol. 2024 Dec;201:110568. doi: 10.1016/j.radonc.2024.110568. Epub 2024 Oct 2. Radiother Oncol. 2024. PMID: 39362607 Clinical Trial.
Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
Wortel RC, Heemsbergen WD, Smeenk RJ, Witte MG, Krol SDG, Pos FJ, Incrocci L. Wortel RC, et al. Among authors: smeenk rj. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1243-1252. doi: 10.1016/j.ijrobp.2017.07.044. Epub 2017 Aug 3. Int J Radiat Oncol Biol Phys. 2017. PMID: 28943074 Clinical Trial.
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
Monninkhof EM, van Loon JWL, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, van den Bergh L, Isebaert S, McColl GM, Smeenk RJ, Noteboom J, Walraven I, Peeters PHM, van der Heide UA. Monninkhof EM, et al. Among authors: smeenk rj. Radiother Oncol. 2018 Apr;127(1):74-80. doi: 10.1016/j.radonc.2017.12.022. Epub 2018 Jan 11. Radiother Oncol. 2018. PMID: 29336835 Free article. Clinical Trial.
In Reply to Güngör et al.
Heemsbergen WD, Wortel RC, Incrocci L, Smeenk RJ, Witte MG, Pos FJ, Krol S. Heemsbergen WD, et al. Among authors: smeenk rj. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1291-1292. doi: 10.1016/j.ijrobp.2017.12.284. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722665 No abstract available.
Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus.
Draulans C, De Roover R, van der Heide UA, Haustermans K, Pos F, Smeenk RJ, De Boer H, Depuydt T, Kunze-Busch M, Isebaert S, Kerkmeijer L. Draulans C, et al. Among authors: smeenk rj. Radiother Oncol. 2019 Nov;140:131-142. doi: 10.1016/j.radonc.2019.06.023. Epub 2019 Jul 2. Radiother Oncol. 2019. PMID: 31276989 Review.
142 results